A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

Exclusion Criteria

• •Clinically significant congenital abnormalities as judged by the study clinicians
• •Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
• •Sickle cell disease
• •Any history of anaphylaxis in relation to vaccination
• •Clinically significant laboratory abnormality as judged by the study clinician
• •Blood transfusion within one month of enrolment
• •Haemoglobin less than 11.3 g/dl for men and less than 10g/dl for in women, where judged to be clinically significant in the opinion of the investigator.
• •Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
• •Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
• •Seropositive for hepatitis B surface antigen (HBsAg) or hepatitis C (HCV IgG)
• •Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin)
• •Women only; pregnancy, or an intention to become pregnant a day before challenge i.e. at C-1
• •Any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
• •Confirmed parasite positive by PCR a day before challenge i.e. at C-1.